News
GSK takes aim at RA market, pitting otilimab against Pfizer ...
GlaxoSmithKline (GSK) has made a serious play for the lucrative rheumatoid arthritis (RA) drug market, announcing the beginning of a phase 3 development programme, involving a new class of
